Claudine Isaacs, MD, and community oncologists weigh ASCENT-03 and ASCENT-04 data, crossover, and toxicity management with ...
GH, discussed letting patients choose between modalities with comparably strong evidence, and the data that shaped his approach.
CancerNetwork is home to the journal Oncology & provides insights on the screening, early detection, diagnosis, treatment and prevention of cancers.
GH, discussed the infrastructure, training, and shared decision-making behind building a prostate HDR brachytherapy program.
IMNI, 16-fraction PMRT with internal mammary node irradiation matched conventional RT for locoregional control with less ...
The June Hot Topics focuses on the challenges venetoclax regimens have faced in multiple myeloma trials. The BCL-2 family regulates cellular apoptosis and survival through interactions between ...
Rutika Mehta, MD, MPH, discussed biomarker testing, PD-L1–low treatment, FLOT dosing, early referral, and ctDNA in ...
The FDA set a June 15, 2027, target action date for sacituzumab tirumotecan in endometrial cancer previously treated with ...
Tyler J. Wilhite, MD, discussed coordinating with rheumatology, orthopedic surgery, and primary care when treating patients with osteoarthritis with low-dose radiation therapy.
Dirk Schadendorf, MD, discussed final STARBOARD data with encorafenib, binimetinib, and pembrolizumab and its role in BRAF V600–mutant melanoma care.
In a retrospective study, high AI-derived whole-body tumor volume on PSMA PET-CT was associated with a 3.20-fold higher risk of death in prostate cancer.
ESMO 2026 posters showed durable EV-302 benefit in older and comorbid populations plus persistent early mortality in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results